-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $26

Benzinga·05/08/2026 13:39:35
Listen to the news
Wedbush analyst Laura Chico maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $27 to $26.